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Background: Recent advances in genetic technology have had a significant impact on the practice of clin-
ical genetics and the diagnosis of genetic syndromes associated with cardiac malformations.
Aim: The present study was aimed to determine whether biomarkers of the folic acid pathway, including
homocysteine and methionine metabolism are altered among non pregnant women who have had a pre-
vious pregnancy affected by congenital heart defects.
Subjects and methods: The study was conducted on 50 women attending the Medical Genetics center and
the Pediatric Cardiology Clinic, Faculty of Medicine, Ain Shams University for follow up. Mothers were
subdivided into: Group 1 (Cases): 25 mothers with a history of congenital heart defects in previous chil-
dren. Group 2 (Controls): 25 mothers and their children didn’t have any birth defects including congenital
heart defects. In both groups women will be excluded: If they were pregnant or taking folate antagonist
medications (antiepileptic drugs) or vitamin supplementations at the time of the study. Measurement of
plasma concentration of: Vitamin B-12, folic acid, Homocysteine, Methionine, S-adenosylmethionine
(SAM) and S-adenosylhomocysteine (SAH), by using Radio immunoassay kit was done.
Results: There is a significant difference between cases and controls as regards history of early neonatal
deaths (28%) in cases versus (4%) in controls (P < 0.05). The study also revealed that the most frequent
congenital cardiovascular malformation is VSD (32%) followed by ASD (20%).As regards biomarker con-
centrations all, were significantly different between case and control subjects except for methionine.
Conclusion: An elevated levels of maternal homocysteine is an independent risk factor for congenital
heart defects. Finally: There is an increasing need for professionals to apply and interpret genetic testing
in a clinically meaningful way for prevention of congenital heart defects.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Congenital heart defects (CHD) are the most common of all con-
genital anomalies, representing a major global health problem.
Heart morphogenesis is a complex process whose disturbance
can produce a range of CHD from harmless to fatal ones [1]. In
addition CHD accounts for the majority of deaths from congenital
defects in childhood, being six times more common than chromo-
somal abnormalities and four more common than neural tube
defects [2]. Reported birth prevalence of CHD varies widely amongstudies worldwide [3]. The estimate of 8 per 1000 live births is
generally accepted as the best approximation [4]. In Egypt the
reported birth prevalence of congenital malformations of the circu-
latory system is 0.13 per 1000 [5].
The etiologies of the majority of heart defects remain unknown
despite their sizable contribution to child morbidity and infant
mortality [6]. About 80% of congenital heart disease (CHD) is mul-
tifactorial and arises through various combinations of genetic and
environmental contributors [7].
Recent advances in genetic technology have had a significant
impact on the practice of clinical genetics and the diagnosis of
genetic syndromes associated with cardiac malformations as well
as sporadic congenital heart disease. These new discoveries have
also expanded our understanding of the contribution of genetic
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ital heart disease [8]. Scientists are making progress in understand-
ing the genetics of heart defects. Since the 1990s, they have
identified about 10 gene mutations that can cause isolated congen-
ital heart disease [9]. In addition environmental factors can con-
tribute to congenital heart defects. Women who contract rubella
during the first three months of pregnancy have a high risk of hav-
ing a baby with a heart defect. Other viral infections, such as the
flu, also may contribute. Exposure to certain industrial chemicals
(solvents), may play a role. Some studies suggest that drinking
alcohol or using cocaine in pregnancy increase the risk of heart
defects [10]. Although genetic and environmental factors are
involved in the etiology of CHD, only approximately 15% can be
attributed to a known cause [7].
Previous epidemiological studies showed that periconceptional
use of multivitamins containing folic acid reduces the risk of hav-
ing a child with CHD [11,12]. Shaw et al., [13] were the first to
show that the maternal use of these vitamins during the sensitive
period of heart development reduced the risk of conotruncal heart
defects in particular. Hernandez-Diaz et al., [14] also suggested
that folate is a key factor in cardiovascular development by show-
ing an increased risk of CHD after maternal exposure to folate
antagonists during the first trimester of pregnancy. The existing
evidence for an association between folic acid and congenital heart
defects, however, is still inconclusive [10].
Homocysteine is the product of the intracellular methionine
cycle in which methionine is initially activated by ATP to S-
adenosylmethionine (SAM), the primary methyl donor for essential
methyl transferase reactions. After methyl transfer, SAM is con-
verted to S-adenosylhomocyteine (SAH). The sole source of homo-
cysteine in the body is the hydrolysis of SAH. Interestingly, the
equilibrium dynamics favor the reverse reaction, thus elevated
homocysteine concentrations cause SAH to accumulate. Increased
SAH is a potent product inhibitor of cellular methyl transferases
which during organogenesis can alter gene expression, cell differ-
entiation and apoptosis which are associated with congenital heart
defects [15].
The aim of the current study is to determine whether biomark-
ers of the folic acid pathway, including homocysteine and
methionine metabolism are altered among non pregnant women
who have had a previous pregnancy affected by congenital heart
defects or not. The results will be compared with those of women
without such a history. This may shed light on new insights into
mechanisms that confer an increased risk of having pregnancies
affected by congenital heart defects.Fig. 1. Standard curve of Homocystiene.2. Subjects and methods
The work has been carried out on 50 mothers. They are divided
into two groups who were attending or were following up in the
Medical Genetics center and the Pediatric Cardiology Clinic, Faculty
of Medicine, Ain Shams University, to establish a maternal risk pro-
file for nonsyndromic congenital heart defects that would enhance
current preventive strategies. Their age ranged from 20 to 39 years
with the mean of 26.59± years. Mothers were divided into:
Group 1 (Cases): 25 mothers with a history of congenital heart
defects in previous children.
Group 2 (Controls): 25 mothers whose previous children were
unaffected by any birth defect including congenital heart defects.
For both groups Time of last pregnancy before participating in
the study ranges between 11 and 18 month.
All study procedures were approved by the Ethics Committee of
Ain Shams University. All included women were interviewed in
person using structured questionnaire and informed orally about
the procedures and the aim of the study and a written consentwas taken to participate in the study. The work is carried out in
accordance with the code of Ethics of the World Medical Associa-
tion (Declaration of Helsinki) for experiments in humans.
All included women were subjected to the following:
A. Full history taking laying stress on mother’s age, full obstet-
ric history, informations about the current use of multivita-
min, cigarettes smoking, caffeine intake, dietary
micronutrient intake including folate, vit B-12 and vit B6,
history of chronic diseases, history of taking medications
(e.g. antiepileptic drugs) and time between last pregnancy
and participation in the study
B. Complete general examination.
C. Withdrawal of a fasting blood sample by routine venipunc-
ture to measure plasma concentration of:




 S-adenosylhomocysteine (SAH).Sample preparation
Blood samples were collected into evacuated tubes containing
EDTA, immediately chilled on ice, and centrifuged at 4000g for
10 min at 4 C. Aliquots of the plasma layer were transferred into
cryostat tubes and stored at 20 C until analysis.
Plasma vitamin B-12 and folic acid concentration
They were measured by using Radio immunoassay kit [Simul
TRAC – SNB RadioAssay kit for Vitamin B-12 (67Co) & Folate (126I)
] MP Biomedicals [16,17].
Plasma(Homocysteine – Methionine-SAH-SAM)
Was measured using High-Performance Liquid chromatography
(HPLC) [18]. HPLC (Beckman) system Gold, dual pump, Mod-
ule:125. Kanauer Injector, with a 20 lL loop. Module 166 variable
UV detector. HPLC column ’’phenomenex’’ (Lichrosorb RP-18;
5 lm, 250  4.6 mm, USA).
Development of standard curves
Standard curves of (Homocystiene-Methionine-SAH-SAM) were
plotted using four different concentrations (2, 10, 50,
Fig. 2. Standard curve of Methionine.
Fig. 3. standard curve of SAH.
Fig. 4. standard curve of SAM.
Table 1
Demonstration of the mean age and SD of cases and controls at the time of study
participation.
Number Range Mean S.D. t P
Cases 25 20–39 27.82 ±5.4305 >0.05 1.614
Controls 25 20–38 25.36 ±5.3454
P-Value: >0.05 Non significant.
Table 2
Time between last pregnancy and participation in the study.
Number Range Mean SD
Cases 25 11–28 16.44 13.070
Controls 25 12–16 12.4 6.6895
Z = 1.331 P = 0.183
Table 3
Correlation between cases and control group as regards environmental & obstetric
history.
Points of compare Case control X2 p-value
No % No %
Educational level
Less than high school 13 52% 7 28% 4.371 0.112
Completed high school 8 32% 8 32%
College education 4 16% 10 40%
Smoking
Negative 18 72% 22 88% 2.000 0.157
Positive 7 28% 3 12%
Dietary caffeine intake 0.000 –
Low 17 68% 17 68%
High 8 32% 8 32%
Vitamin supplementation 5.195 0.023
Negative 18 72% 10 40%
Positive 7 28% 5 60%
History of Abortion 3.000 0.83
Negative 12 48% 18 72%
Positive 13 52% 7 28%
History of Still-births 3.191 0.74
Negative 22 88% 25 100
Positive 3 12% 0 0
History of Early neonatal deaths 5.357 0.021
Negative 18 72% 24 96
Positive 7 28% 1 4
Total number of cases No %
Case 25 100
Control 25 100
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determined and entered against concentration of the standard to
plot the standard curves (Figs. 1–4).Statistical method
IBM SPSS statistics (V.21.0,IBM Corp; USA,2012) was used for
data analysis. Data were expressed as Mean – SD for quantitative
parametric measures in addition to Median Percentiles for quanti-
tative non-parametric measures and both number and percentage
for categorized data.3. Results
Mothers’ ages in cases ranged between 20 and 39 years with
mean of ±27.82 years and in controls ranged between 20 and
38 years with mean of ±25.36 years with no significant difference
between them (P > 0.05) (Table 1). The educational level was less
than high school in the majority of cases (52%), while in the con-
trols the majority (40%) were college educate. However the educa-
tional level did not vary significantly between the two groups
(P > 0.05). There was no significant difference between the two
Table 4
Categories of congenital heart disease in previous pregnancies of cases.
Category Number Percent








Valvular lesions P.S. 2 8%
Coarc 1 4%
Single ventricle 1 4%
Total 4 16%
Abbreviations: VSD = Ventricular septal defect. ASD = Atrial septal defect. PDA = -
patent ductus arteriosus. PS = Pulmonary stenosis. Coarc = Coarctation of aorta
TGA = Transposition of great vessels. DORV = Double outlet right ventricle.
Fig. 5. Shows comparison between patients and controls as regards plasma
concentrations of (1) Homocysteine-(2) Methionine (3) SAM-(4) SAH.
Fig. 6. Shows comparison between patients and controls as regards plasma
concentrations of folic acid.
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tobacco smoke or caffeine intake (P >0.05). There was no signifi-
cant difference between group 1 and group 2 as regards the time
of last pregnancy and date of blood withdrawal for study participa-
tion (P > 0.05) (Table 2). There is a significant difference between
cases and controls as regards history of still births(12% in cases
in contrast to 0% in controls). Also There is a significant difference
between cases and controls as regards history of early neonatal
deaths (28% in cases versus 4% in controls) (P < 0.05) (Table 3).
The most frequent reported congenital cardiovascular malforma-
tions in our study is ventricular septal defect (VSD) (32%) and the
next malformation in frequency is atrial septal defect (ASD) 20%
Table 4. All biomarker concentrations, except for methionine, were
significantly higher in cases than controls (P < 0.05) (Cases had
higher mean homocysteine (48.028 nmol/L), SAH (21.578 n mol/
L) and SAM (14.283 n mol/L) concentrations while controls had
higher mean methionine (96.402 nmol/L) concentrations (Table 5,
Fig. 5). The mean folic acid and vitamin B12 concentrations for con-
trols were significantly higher than that for cases (10.645 ng/mL
vesus 6.672 ng/mL) and (882.5 pg/mLversus 523.4 pg/mL)
consecutively (Table 5, Fig. 6). Also there was a positive significant
correlation between S-adenosylhomocyteine (SAH) and
S-adenosylmethionine (SAM) [r = 0.495 p = 0.012], among cases.
While there was a negative highly significant correlation between
(SAM) and (Vit-B12) [r = 0.636, p < 0.001] (Table 6).Table 5
Plasma biomarkers concentrations among cases and controls.
Biomarker Cases Controls P
n Mean ± SD Median (min,max) n Mean ± SD Median (min, max)
Homocysteine (nmol/L) 25 48.028 (19.469) 50.474 (16.38
93.61)




















































SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine.
Table 6
Correlation between maternal biomarkers among cases and control group.
Homocysteine Methionine Folic-acid Vit-B12 SAM
Case Control Case Control Case Control Case Control Case Control
SAH r = 0.198 0.007 r = 0.285 0.18 r = 0.124 0.167 r = 0.273 0.077 r = 0.495 0.335
p = 0.342 0.975 p = 0.167 0.39 p = 0.556 0.435 p = 0.186 0.72 p = 0.012 0.102
SAM r = 0.028 0.243 r = 0.074 0.19 r = 0.161 0.034 r = 0.636 0.077
p = 0.893 0.242 P = 0.726 0.363 p = 0.442 0.875 p = 0.001 0.72
Vit-B12 r = 0.155 0.325 r = 0.017 0.035 r = 0.267 0.177
p = 0.46 0.087 p = 0.937 0.87 p = 0.198 0.408
Folic-acid r = 0.145 0.032 r = 0.274 0.361
p = 0.488 0.883 p = 0.184 0.083
Methionine r = 0.378 0.69
p = 0.062 0.742
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Risk factors for CHDs have to be identified in order to develop
and implement effective primary prevention programs. Preconcep-
tional screening of these risk factors and the development of
(nutritional) interventions will contribute to future risk assess-
ment and, thereby, prevention of CHDs. The maternal nutritional
status has been shown to be involved in the pathogenesis of
related birth defects [19].
In our study the majority of cases were low educated (52%),
while 40% of controls were highly educated. These findings are
consistent with Lu et al., [20] who reported that dietary vitamin
B12 is only available from animal sources like fish and red meat.
Therefore, low educated people may not have enough income for
these more expensive foods or they are not correctly informed to
buy and prepare healthy food.
In the current study history of abortion and early neonatal
deaths were significantly higher among cases than controls
[(52%) versus (28%), (28%) versus (4%)] consecutively. The increase
in total plasma maternal homocysteine (tHcy) among our cases
could be the cause of these adverse pregnancy outcomes as it is
a strong and independent risk factor for vascular disease. Similar
results were obtained by Burke et al., [21] who reported similar
relations between total homocysteine (tHcy) concentration and
congenital heart, premature delivery, recurrent abortions,
preeclampsia and placental abruption.
In the current study history of taking vitamins supplementation
before and during pregnancy was (60% in controls versus 28% in
cases). This was in agreement with Lorenzo et al., [22] study who
found that women using multivitamin supplements in the pericon-
ceptional period were at significantly lower risk of having babies
with congenital heart defects than women not using multivitamins.
In our study, we found that VSD was the most common lesion
reported (32%) followed by ASD (20%). This coincides with Zaher
and Abd Elmohsen [23] who reported that VSD was the most com-
mon congenital heart defect (30.6%). However Lin et al., [24]
reported that VSD represents 15.7% of their cases. Factors, such
as spontaneous closure of the lesion, and the non recognition of
minimum or small septal defects by the physician responsible for
primary care, may have contributed to the difference between
our figures and those in other studies. Therefore, the incidence of
VSD will be much higher if all newborns are examined, lower if
only those newborns with murmurs are examined and lower still
if accession of these subjects is delayed until one year of age
[25]. As regards cyanotic heart defects, tetralogy of fallot was the
most frequent type recorded 12%, followed by transposition of
great arteries 8%, and double outlet right ventricle 4%. Complex
defects, which prevailed in other studies, manifesting in the first
days of life, such as hypoplastic left ventricle, single ventricle and
Ebstein’s anomaly were less frequently found in our study. Becausethese patients die early, we may suppose that many of them didn’t
receive specialized care in the proper time or even die without a
diagnosis [26]. The results of our study shows that plasma concen-
trations of homocysteine (48.028 nmol/L), SAH (21.578 nmol/L)
and SAM (14.283 nmol/L) were significantly elevated among case
subjects while plasma concentration of vitamin B12 (882.5 pg/
mL) and folic acid (10.654 ng/mL) were significantly elevated
among control subjects. There was no significant difference in
plasma concentration of methionine between cases and controls.
Possible causes for the altered biomarkers include deficiencies in
folate or vitamin B-12 or both, genetic polymorphisms encoding
enzymes in the methionine cycle, or exogenous factors [15]. The
hyperhomocysteinaemia among the cases can largely be explained
by the significantly lower folate and/ or vitamin B12 status. There-
fore, malnutrition and polymorphisms in folate and vitamin B12
genes may play a role. Other causes of the maternal hyperhomo-
cysteinaemia, however, have to be considered as well, such as
low vitamin B2 or B6 levels, high body mass index (BMI) or glucose
intolerance [27].
Folate and vitamin B12 are involved in the remethylation of
homocysteine and donation of one-carbon groups to proteins,
lipids and nucleotides, whereas vitamin B6 is important in the
transsulphuration of homocysteine [28]. The reduced plasma con-
centration of vitamin B12 and folic acid among cases suggested
that folate is a key factor in cardiovascular development. Insuffi-
cient intake of B-vitamins results in biochemical derangements
leading to hyperhomocysteinemia and DNA hypomethylation that
may contribute to the development of CHDs [29].
Our findings of elevated homocysteine among case subjects are
consistent with other studies comparing vitamin-dependent
homocysteine metabolism among mothers of offspring with con-
genital heart defects [15], orofacial clefts [30] and neural tube
defects (NTDs) [31] with those of mothers with normal formed off-
spring. Possible mechanisms by which homocysteine may have an
embryotoxic effect include; elevated homocysteine may have an
indirect embryotoxic effect by increasing oxidative stress through
excessive production of reactive oxygen species and by decreasing
the glutathione-dependent antioxidant-defense mechanisms [32].
Chronic oxidative stress is also associated with low concentrations
of vitamin B-6, reduced glutathione (GSH), and cysteine and high
concentrations of oxidized glutathione (GSSG) [33]. Furthermore,
lifestyle factors such as alcohol intake and cigarette smoking are
associated with increased oxidative stress, which can decrease
the functional activity of methionine synthase through limiting
the availability of reduced vitamin B-12 [34]. In our sample the
number of smokers among case subjects was relatively higher than
among control subjects, but the results were not significantly dif-
ferent. We examined our data to determine whether the concen-
trations of homocysteine and folate are correlated with the time
interval between the end of pregnancy and the blood drawn in case
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fore, it is likely that, the metabolic patterns observed even more
than a year after pregnancy reflect stable adult profiles.
To conclude, A high maternal homocysteine concentration is
associated with an increased risk of having a child with CHD, in
addition low maternal folate and Vitamin B-12 intakes detrimen-
tally affect the embryonic cardiovascular development. Several
methodologic limitations of our study should be considered, as
venipuncture was done after the pregnancies had ended. Thus,
our measurements may not represent the biomarker concentra-
tions at the time of organogenesis.
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